Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022;21(3):456–62.

Article  PubMed  Google Scholar 

Ong T, Ramsey BW. Cystic fibrosis: a review. JAMA. 2023;329(21):1859–71.

Article  CAS  PubMed  Google Scholar 

Jia S, Taylor-Cousar JL. Cystic fibrosis modulator therapies. Annu Rev Med. 2023;74:413–26.

Article  CAS  PubMed  Google Scholar 

Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lopez A, Daly C, Vega-Hernandez G, MacGregor G, Rubin JL. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J Cyst Fibros. 2023;22(4):607–14.

Article  CAS  PubMed  Google Scholar 

Ostrenga JS, Robinson K, Brown AW, Goss CH, Cromwell EA. Aging with CF: characteristics of people with CF aged 40 and older in the United States. J Cyst Fibros. 2025;24(1):183–6.

Article  PubMed  Google Scholar 

Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax. 2007;62(4):360–7.

Article  PubMed  PubMed Central  Google Scholar 

Flume PA, Robinson KA, O’Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009;54(4):522–37.

PubMed  Google Scholar 

McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol. 2021;56(6):1496–503.

Article  PubMed  PubMed Central  Google Scholar 

Desai M, Hine C, Whitehouse JL, Brownlee K, Charman SC, Nagakumar P. Who are the 10%? Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies. Respir Med. 2022;199: 106878.

Article  PubMed  Google Scholar 

Dagenais RVE, Su VCH, Quon BS. Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review. J Clin Med. 2020;10(1):23.

Article  PubMed  PubMed Central  Google Scholar 

Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA, Sawicki GS, et al. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respir Med. 2023;11(4):329–40.

Article  CAS  PubMed  Google Scholar 

Szentpetery S, Fernandez GS, Schechter MS, Jain R, Flume PA, Fink AK. Obesity in cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry. J Cyst Fibros. 2022;21(5):777–83.

Article  PubMed  PubMed Central  Google Scholar 

Freswick PN, Reid EK, Mascarenhas MR. Pancreatic enzyme replacement therapy in cystic fibrosis. Nutrients. 2022;14(7):1341.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abraham JM, Taylor CJ. Cystic fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer. J Cyst Fibros. 2017;16(Suppl 2):S40–9.

Article  PubMed  Google Scholar 

Putman MS, Norris AW, Hull RL, Rickels MR, Sussel L, Blackman SM, et al. Cystic fibrosis-related diabetes workshop: research priorities spanning disease pathophysiology, diagnosis, and outcomes. Diabetes. 2023;72(6):677–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Granados A, Chan CL, Ode KL, Moheet A, Moran A, Holl R. Cystic fibrosis related diabetes: pathophysiology, screening and diagnosis. J Cyst Fibros. 2019;18(Suppl 2):S3-s9.

Article  PubMed  Google Scholar 

Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros. 2013;12(4):318–31.

Article  PubMed  Google Scholar 

Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697–708.

Article  PubMed  PubMed Central  Google Scholar 

Chan CL, Ode KL, Granados A, Moheet A, Moran A, Hameed S. Continuous glucose monitoring in cystic fibrosis—a practical guide. J Cyst Fibros. 2019;18(Suppl 2):S25-s31.

Article  CAS  PubMed  Google Scholar 

Geyer MC, Sullivan T, Tai A, Morton JM, Edwards S, Martin AJ, et al. Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: a randomized crossover trial. Diabetes Obes Metab. 2019;21(3):700–4.

Article  CAS  PubMed  Google Scholar 

Santhakumar A, Lewis F, Pickles J, Winterbottom H, Punt S, Beynon J, et al. Role for DPP4 inhibitor therapy in cystic fibrosis related diabetes: a single centre experience. J Cyst Fibros. 2024;23(5):853–6.

Article  CAS  PubMed  Google Scholar 

Gnanapragasam H, Mustafa N, Bierbrauer M, Andrea Providence T, Dandona P. Semaglutide in cystic fibrosis-related diabetes. J Clin Endocrinol Metab. 2020;105(7):2341.

Article  Google Scholar 

Schwarzenberg SJ, Thomas W, Olsen TW, Grover T, Walk D, Milla C, Moran A. Microvascular complications in cystic fibrosis-related diabetes. Diabetes Care. 2007;30(5):1056–61.

Article  PubMed  Google Scholar 

Goetz DM, Brown RF, Filigno SS, Bichl SL, Nelson AL, Merlo CA, et al. Cystic fibrosis foundation position paper: redefining the CF care model. J Cyst Fibros. 2024;23:1055.

Article  CAS  PubMed  Google Scholar 

Paccou J, Zeboulon N, Combescure C, Gossec L, Cortet B. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcif Tissue Int. 2010;86(1):1–7.

Article  CAS  PubMed  Google Scholar 

Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005;90(3):1888–96.

Article  CAS  PubMed  Google Scholar 

Cairoli E, Eller-Vainicher C, Morlacchi LC, Tarsia P, Rossetti V, Pappalettera M, et al. Bone involvement in young adults with cystic fibrosis awaiting lung transplantation for end-stage respiratory failure. Osteoporos Int. 2019;30(6):1255–63.

Article  CAS  PubMed  Google Scholar 

Anabtawi A, Le T, Putman M, Tangpricha V, Bianchi ML. Cystic fibrosis bone disease: pathophysiology, assessment and prognostic implications. J Cyst Fibros. 2019;18(Suppl 2):S48-s55.

Article  PubMed  Google Scholar 

Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jeffery TC, Chang AB, Conwell LS. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev. 2023;1(1):Cd002010.

PubMed